News Tag: news

Preparing for the NRG Quality Assurance Audit

Read More

FORTE STUDY UPDATE: NRG-CC005/FORTE Trial Communications

Read More

A Randomized Phase II Trial of Immunotherapy with Dual Immune Checkpoint Inhibitors Compared to Anti-PD1 Monotherapy in Patients with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma (NRG-GY025)

Read More

A Study Champion Perspective: Christina Henson, MD

Read More

Upcoming Trial Highlight: Studying Stereotactic Radiosurgery Before Versus After Surgery for Patients with Resectable Brain Metastases (NRG-BN012)

Read More

NRG-BN011 Seeks to Improve Treatment Outcomes in a Substantial Subset of Glioblastoma Patients with Dual Alkylating Therapy

Read More

A Safety Run-in and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma (NRG-BN010)

Read More

NRG Oncology Study of Photon Versus Proton Therapy for Patients with Newly Diagnosed Glioblastoma Completes Accrual

Read More

NRG Oncology Board of Directors Member, Dr. Priya Rastogi named NSABP Foundation CEO

Read More

NRG Oncology Executive Director is Stepping Down from the Position

Read More